Citadel Advisors
URGN icon

Citadel Advisors’s UroGen Pharma URGN Stock Holding History

Citadel Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Sell
15,300
-40,600
-73% -$814K ﹤0.01% 10668
2025
Q4 		$1.31M Sell
55,900
-29,900
-35% -$649K ﹤0.01% 6816
2025
Q3 		$1.71M Sell
85,800
-89,000
-51% -$1.6M ﹤0.01% 6393
2025
Q2 		$2.39M Buy
174,800
+103,600
+146% +$994K ﹤0.01% 5383
2025
Q1 		$787K Buy
71,200
+13,500
+23% +$144K ﹤0.01% 7489
2024
Q4 		$615K Buy
57,700
+47,900
+489% +$573K ﹤0.01% 8096
2024
Q3 		$124K Sell
9,800
-15,200
-61% -$226K ﹤0.01% 10825
2024
Q2 		$420K Buy
25,000
+2,600
+12% +$37K ﹤0.01% 8419
2024
Q1 		$336K Buy
22,400
+1,400
+7% +$22.9K ﹤0.01% 9223
2023
Q4 		$315K Sell
21,000
-6,500
-24% -$84.4K ﹤0.01% 9063
2023
Q3 		$385K Buy
27,500
+17,400
+172% +$279K ﹤0.01% 8633
2023
Q2 		$105K Sell
10,100
-45,700
-82% -$504K ﹤0.01% 10868
2023
Q1 		$516K Sell
55,800
-39,000
-41% -$359K ﹤0.01% 8239
2022
Q4 		$841K Buy
94,800
+74,900
+376% +$709K ﹤0.01% 7149
2022
Q3 		$166K Buy
+19,900
New +$165K ﹤0.01% 10608
2021
Q4 		– Sell
-36,800
Closed -$619K – 14794
2021
Q3 		$619K Sell
36,800
-700
-2% -$11.1K ﹤0.01% 9357
2021
Q2 		$573K Buy
37,500
+11,200
+43% +$203K ﹤0.01% 9751
2021
Q1 		$512K Buy
+26,300
New +$558K ﹤0.01% 9628
2020
Q3 		– Sell
-23,900
Closed -$624K – 10767
2020
Q2 		$624K Sell
23,900
-86,700
-78% -$2.12M ﹤0.01% 6672
2020
Q1 		$1.97M Sell
110,600
-2,400
-2% -$64.8K ﹤0.01% 4166
2019
Q4 		$3.77M Buy
113,000
+96,300
+577% +$2.63M ﹤0.01% 3470
2019
Q3 		$398K Buy
+16,700
New +$546K ﹤0.01% 7145

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Citadel Advisors's URGN Position: Q1 2026 in Review

Citadel Advisors reduced its UroGen Pharma (URGN) stake by 64% in Q1 2026, selling an estimated $9.42M and leaving 267,996 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4400.

Citadel Advisors first reported a position in URGN in Q1 2018 and has held it in 30 quarters since. The position peaked at $17.7M in Q3 2018. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Citadel Advisors held 267,996 shares of UroGen Pharma worth $4.82M as of Q1 2026.
  • Citadel Advisors sold 469,761 UroGen Pharma shares in Q1 2026, an estimated $9.42M.
  • UroGen Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4400 holding.
  • Citadel Advisors first reported a position in UroGen Pharma in Q1 2018 and has held it in 30 quarters since.
  • Citadel Advisors's UroGen Pharma position peaked at $17.7M in Q3 2018.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.